Effect and mechanism of Musashi2 and related signal pathways in genesis and progression of malignant tumorLi Jiarun, Ge Qiaofeng, Guo Geng, Wang Xiaogang.

doi:10.3760/cma.j.issn.1673422X.2017.03.008作

Journal of International Oncology ›› 2017, Vol. 44 ›› Issue (3): 190-192.doi: 10.3760/cma.j.issn.1673422X.2017.03.008作

Previous Articles Next Articles

Effect and mechanism of Musashi2 and related signal pathways in genesis and progression of malignant tumorLi Jiarun, Ge Qiaofeng, Guo Geng, Wang Xiaogang.

Li Jiarun, Ge Qiaofeng, Guo Geng, Wang

100034 北京大学第一医院老年病科（李佳润）；山西医科大学第二医院骨科（葛乔枫）；山西医科大学第一医院神经外科（郭庚、王小刚）

Online:2017-03-08 Published:2017-02-28
Contact: Guo Geng E-mail:guogeng973@163.com
Supported by:
National

Natural Science Foundation of China (81201991); China Postdoctoral Science

Foundation (2015M571068, 2016T90115); Project Supported by Beijing

Postdoctoral Research Foundation (2015ZZ56, 2016ZZ43); Natural Science

Foundation of Shanxi Province of China (201601D011127); Program for the

Outstanding Innovative Teams of Higher Learning Institutions of Shanxi

Province (20138); Scientific Research Subject of Shanxi Provincial Health

Department (201301066)

Abstract

Abstract: In mammals, there are two RNAbinding proteins, Musashi (Msi)1 and Msi2, constituting the Msi family. Msi2 is mainly distributed among neural, hematopoietic, gastrointestinal, pancreatic and epithelial stem cells. It is of great importance to maintain the balance between proliferation and differentiation of stem cells and regulate their growth and development. The changed expression of this protein will induce genesis and progression of malignant tumor through many kinds of signal pathways. Thus, Msi2 is trusted to provide a predictive mark and a therapeutic target for related tumors.

Key words: Neoplasms, Mechanism, Musashi2

Li Jiarun, Ge Qiaofeng, Guo Geng, Wang . Effect and mechanism of Musashi2 and related signal pathways in genesis and progression of malignant tumorLi Jiarun, Ge Qiaofeng, Guo Geng, Wang Xiaogang.[J]. Journal of International Oncology, 2017, 44(3): 190-192.

References

［1］ Sutherland JM, Sobinoff AP, Gunter KM, et al. Knockout of RNA binding protein Msi2 impairs follicle development in the mouse ovary: characterization of Msi1 and Msi2 during folliculogenesis［J］. Biomolecules, 2015, 5(3): 1228-1244. DOI: 10.3390/biom5.31228. ［2］ Sutherland JM, Fraser BA, Sobinoff AP, et al. Developmental expression of musashi1 and musashi2 RNAbinding proteins during spermatogenesis: analysis of the deleterious effects of dysregulated expression［J］. Biol Reprod, 2014, 90(5): 92. DOI: 10.1095/biolreprod.113.115261. ［3］ Taggart J, Ho TC, Amin E, et al. MSI2 is required for maintaining activated myelodysplastic syndrome stem cells［J］. Nat Commun, 2016, 7: 10739. DOI: 10.1038/ncomms10739. ［4］ Han YX, Ye AF, Zhang Y, et al. Musashi2 silencing exerts potent activity against acute myeloid leukemia and enhances chemosensitivity to daunorubicin［J］. PLoS One, 2015, 10(8): e0136484. DOI: 10.1371/journal.pone.0136484. ［5］ Kaeda J, Ringel F, Oberender C, et al. Upregulated MSI2 is associated with more aggressive chronic myeloid leukemia［J］. Leuk Lymphoma, 2015, 56(7): 21052113. DOI: 10.3109/10428194.2014.981175. ［6］ de AndrésAguayo L, Varas F, Graf T. Musashi 2 in hematopoiesis［J］ . Curr Opin Hematol, 2012, 19(4): 268-272. DOI: 10.1097/MOH.0b013e328353c778. ［7］ Park SM, Deering RP, Lu YH, et al. Musashi2 controls cell fate, lineage bias, and TGFbeta signaling in HSCs［J］. J Exp Med, 2014, 211 (1): 71-87. DOI: 10.1084/jem.20130736. ［8］ Zhang HJ, Tan S, Wang J, et al. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway［J］. Exp Cell Res, 2014, 320(1): 119-127. DOI: 10.1016/j.yexcr.2013.09.009. ［9］ Park SM, Genen M, Vu L, et al. Musashi2 sustains the mixedlineage leukemiadriven stem cell regulatory program［J］. J Clin Invest, 2015, 125(3): 1286-1298. DOI: 10.1172/JCI78440. ［10］ Thol F, Winschel C, Sonntag AK, et al. Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia［J］. Ann Hematol, 2013, 92(3): 315-323. DOI: 10.1007/s00277012 16375. ［11］ Di Giacomo D, Pierini V, Barba G, et al. Blast crisis Ph+ chronic myeloid leukemia with NUP98/HOXA13 upregulating MSI2［J］. Mol Cytogenet, 2014, 7: 42. DOI: 10.1186/17558166742. ［12］ GarcíaAlegría E, Carmen LafitaNavarro M, Aguado R, et al. NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells［J］. Cancer Lett, 2016, 375(1): 92-99. DOI: 10.1016/j.canlet.2016.02.037. ［13］ Wang MH, Qin SY, Zhang SG, et al. Musashi2 promotes hepatitis B virus related hepatocellular carcinoma progression via the Wnt/betacatenin pathway［J］. Am J Cancer Res, 2015, 5(3): 1089-1100. ［14］ He L, Zhou XK, Qu C, et al. Musashi2 predicts poor prognosis and invasion in hepatocellular carcinoma by driving epithelialmesenchymal transition［J］. J Cell Mol Med, 2014, 18(1): 49-58. DOI: 10.1111/jcmm.12158. ［15］ Wang S, Li N, Yousefi M, et al. Transformation of the intestinal epithelium by the MSI2 RNAbinding protein［J］. Nat Commun, 2015, 6: 6517. DOI: 10.1038/ncomms7517. ［16］ Sutherland JM, McLaughlin EA, Hime GR, et al. The musashi family of RNA binding proteins: master regulators of multiple stem cell populations［J］. Adv Exp Med Biol, 2013, 786: 233-245. DOI: 10.1007/978 9400766211_13. ［17］ Cox JL, Wilder PJ, Gilmore JM, et al. The SOX2interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells［J］. PLoS One, 2013, 8(5): e62857. DOI: 10.1371/journal.pone.0062857. ［18］ Shi K, Bing ZT, Cao GQ, et al. Identify the signature genes for diagnose of uveal melanoma by weight gene coexpression network analysis［ J］. Int J Ophthalmol, 2015, 8(2): 269-274. DOI: 10.3980/j.issn.22223959.2015.02.10. ［19］ EmadiBaygi M, Nikpour P, MohammadHashem F, et al. MSI2 expression is decreased in grade Ⅱ of gastric carcinoma［J］. Pathol Res Pract, 2013, 209(11): 689-691. DOI: 10.1016/j.prp.2013.07.008. ［20］ Wuebben EL, Mallanna SK, Cox JL, et al. Musashi2 is required for the selfrenewal and pluripotency of embryonic stem cells［J］. PLoS One, 2012, 7(4): e34827. DOI: 10.1371/journal.pone.0034827. ［21］ Bennett CG, Riemondy K, Chapnick DA, et al. Genomewide analysis of Musashi2 targets reveals novel functions in governing epithelial cell migration［J］. Nucleic Acids Res, 2016, 44(8): 3788-3800. DOI: 10.1093/nar/gkw207.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.

Effect and mechanism of Musashi2 and related signal pathways in genesis and progression of malignant tumorLi Jiarun, Ge Qiaofeng, Guo Geng, Wang Xiaogang.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments